Back to Search Start Over

National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017–2020

Authors :
Po-Yu Liu
Chi-Ying Lin
Yu-Hui Chen
Ting-Shu Wu
Yen-Hsu Chen
Muh Yong Yen
Pei-Lan Shao
Lih-Shinn Wang
Wen Sen Lee
Fu-Der Wang
Yu-Lin Lee
Zhi-Yuan Shi
Wang-Huei Sheng
Min-Chi Lu
Shu-Hui Tseng
Yao-Shen Chen
Wen Chien Ko
Po-Ren Hsueh
Shu-Hsing Cheng
Ying-Chun Chien
Chang-Pan Liu
Po-Liang Lu
Chun-Ming Lee
Source :
Journal of Global Antimicrobial Resistance, Journal of Global Antimicrobial Resistance, Vol 26, Iss, Pp 308-316 (2021)
Publication Year :
2021
Publisher :
The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy., 2021.

Abstract

Objectives The aim of this study was to investigate the trends in serotypes and in vitro antimicrobial susceptibility of Streptococcus pneumoniae causing adult invasive pneumococcal disease (IPD) to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics from 2017–2020 following implementation of the 13-valent pneumococcal conjugate vaccine (PCV-13) and during the COVID-19 (coronavirus disease 2019) pandemic. Methods During the study period, 237 S. pneumoniae isolates were collected from non-duplicate patients, covering 15.0% of IPD cases in Taiwan. Antimicrobial susceptibility testing was performed using a Sensititre® system. A latex agglutination method (ImmuLex™ Pneumotest Kit) was used to determine serotypes. Results Susceptibility rates were high for vancomycin (100%), teicoplanin (100%) and linezolid (100%), followed by ceftaroline (non-meningitis) (98.3%), moxifloxacin (94.9%) and quinupristin/dalfopristin (89.9%). MIC50 and MIC90 values of dalbavancin, telavancin, tedizolid, eravacycline and omadacycline were generally low. Non-vaccine serotype 23A was the leading cause of IPD across the adult age range. Isolates of serotype 15B were slightly fewer than those of PCV-13 serotypes in patients aged ≥65 years. The overall case fatality rate was 15.2% (36/237) but was especially high for non-PCV-13 serotype 15B (21.4%; 3/14). Vaccine coverage was 44.7% for PCV-13 and 49.4% for the 23-valent pneumococcal polysaccharide vaccine (PPSV-23), but was 57% for both PCV-13 and PPSV-23. Conclusion The incidence of IPD was stationary after PCV-13 introduction and only dramatically decreased in the COVID-19 pandemic in 2020. The MIC50 and MIC90 values of dalbavancin, telavancin, tedizolid, eravacycline, omadacycline were generally low for S. pneumoniae causing adult IPD.

Details

Language :
English
ISSN :
22137173 and 22137165
Volume :
26
Database :
OpenAIRE
Journal :
Journal of Global Antimicrobial Resistance
Accession number :
edsair.doi.dedup.....e11804e1d8977c3f00cdbb7b5db9165e